Results 31 to 40 of about 85,787 (336)

Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells [PDF]

, 2015
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and incurable disease. Poor prognosis is due to multiple reasons, including acquisition of resistance to gemcitabine, the first-line chemotherapeutic approach.
Bielli, P, Calabretta, S, Capurso, G, DELLE FAVE, Gianfranco, Fendrich, V, Passacantilli, I, Pilozzi, Emanuela, Sette, C.   +7 more
core   +2 more sources

Metabolism remodeling in pancreatic ductal adenocarcinoma

Cell Stress, 2019
Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of death of patients with malignant cancers by 2030. Current options of PDAC treatment are limited and the five-year survival rate is less than 8%, leading to an ...
Jin-Tao Li, Yi-Ping Wang, Miao Yin, Qun-Ying Lei   +3 more
doaj   +1 more source

Inhibition of HIF-1 alpha by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma [PDF]

, 2015
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
Acland, Assenat, Bazhin, Carbone, Chaput, Chen, Chouaib, Danenberg, David, Dyson, El-Deiry, Gallick, Gelovani, Ghansah, Giese, Gil, Gress, Gribben, Hao, Hao, Hao, Henson, Jemal, Kiessling, Kroemer, Kroemer, Kroemer, Levi, Luo, Mi, Moses, Plate, Powis, Powis, Powis, Ravichandran, Ricci, Rodeck, Sarker, Schuler, Semenza, Singh, Spisek, Tani, Vandenabeele, Wang, Wang, Zitvogel, Zitvogel, Zitvogel   +49 more
core   +1 more source

Fibroblasts shape PDAC architecture [PDF]

Nature Reviews Cancer, 2019
Ligorio, Sil et al. used a combination of single-cell RNA and proteomic techniques in both model systems and human pancreatic ductal adenocarcinomas (PDACs) to better understand the interplay between cancer cells and fibroblasts, and the implications of this for PDAC progression.
openaire   +2 more sources

Tumor-Reprogrammed Stromal BCAT1 Fuels Branched Chain Ketoacid Dependency in Stromal-Rich PDAC Tumors

Nature Metabolism, 2020
Branched-chain amino acids (BCAAs) supply both carbon and nitrogen in pancreatic cancers, and increased levels of BCAAs have been associated with increased risk of pancreatic ductal adenocarcinomas (PDACs).
Ziwen Zhu, Abhinav Achreja, Noah Meurs, Olamide Animasahun, Sarah Owen, Anjali Mittal, P. Parikh, Ting-Wen Lo, J. Franco-Barraza, Jiaqi Shi, Valerie Gunchick, M. Sherman, E. Cukierman, Andrew M. Pickering, A. Maitra, V. Sahai, M. Morgan, S. Nagrath, T. Lawrence, Deepak Nagrath   +19 more
semanticscholar   +1 more source

Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC

Journal of Immunological Research, 2021
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies and is known for its high resistance and low response to treatment. Tumor immune evasion is a major stumbling block in designing effective anticancer therapeutic strategies ...
Kai-Xia Zhou, Shan Huang, Lipeng Hu, Xueli Zhang, Wei-Ting Qin, Yanli Zhang, Linli Yao, Yan-qiu Yu, Yao-Qi Zhou, Lei Zhu, J. Ji, Zhi-gang Zhang   +11 more
semanticscholar   +1 more source

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma [PDF]

, 2016
Immunotherapy approaches for pancreatic ductal adenocarcinoma (PDAC) have met with limited success. It has been postulated that a low mutation load may lead to a paucity of T cells within the tumor microenvironment (TME).
Alvarez, Hector A., Bailey, Peter, Biankin, Andrew V., Chang, David K., Chattopadhyay, Chandrani, Ekmekcioglu, Suhendan, Forget, Marie-Andrée, Grimm, Elizabeth A., Haymaker, Cara, Hwu, Patrick, Kim, Sun-Hee, Maitra, Anirban, Roszik, Jason, San Lucas, Francis A.   +13 more
core   +1 more source

PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC

Signal Transduction and Targeted Therapy, 2020
High expression of PD-L1 marks the poor prognosis of pancreatic ductal adenocarcinomas (PDAC). However, the regulatory mechanism of PD-L1 remains elusive.
Xiuchao Wang, Xin Li, Xunbin Wei, Hai-ping Jiang, Chungen Lan, Shengyu Yang, Han Wang, Yanhui Yang, Caijuan Tian, Zanmei Xu, Jiangyan Zhang, J. Hao, H. Ren   +12 more
semanticscholar   +1 more source

Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer. [PDF]

, 2018
BACKGROUND:Although canonical Wnt signaling is known to promote tumorigenesis in pancreatic ductal adenocarcinoma (PDAC), a cancer driven principally by mutant K-Ras, the detailed molecular mechanisms by which the Wnt effector β-catenin regulates such ...
Chen, Yibu, Genyk, Yuri S, Kahn, Michael, Lai, Keane KY, Lenz, Heinz-Josef, Lin, David P, Manegold, Philipp, Nguyen, Cu, Pandol, Stephen J, Teo, Jia-Ling, Wu, Kaijin, Wu, Yongfeng, Zhao, Yi   +12 more
core   +2 more sources

Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids

International Journal of Nanomedicine, 2021
Julian Palzer,1,2 Benedikt Mues,2 Richard Goerg,1,2 Merel Aberle,3 Sander S Rensen,3 Steven WM Olde Damink,1,3 Rianne DW Vaes,3 Thorsten Cramer,1,3 Thomas Schmitz-Rode,2 Ulf P Neumann,1,3 Ioana Slabu,2 Anjali A Roeth1,3 1Department of General, Visceral ...
Palzer J, Mues B, Goerg R, Aberle M, Rensen SS, Olde Damink SWM, Vaes RDW, Cramer T, Schmitz-Rode T, Neumann UP, Slabu I, Roeth AA   +11 more
doaj